title: [The use of Smecta for the treatment of the basic digestive tract diseases].
abstract: The indices for the gastric contents aggression and protection ratio returned to normal in patients with peptic ulcer and preulcerous condition during the treatment with smekta due to a decrease in proteolytic activity and increase in the synthesis of the mucus protective proteins. Monitoring of intragastric pH in the body of the stomach throughout 24 hours in patients with peptic ulcer of duodenal location revealed significant acid-neutralizing effect of smekta. Patients with nonspecific ulcerous colitis enjoyed freedom of side effects as a result of the use of salofalk and derived full therapeutic benefit from this treatment. Under the effect of smekta there occurred suppression of the growth of pathogenic proteolytic flora, improvement of qualitative properties of coli flora and growth of sugar-lytic flora in patients with intestinal dysbiosis. According to the data available, smekta strengthens the mucous barrier by improving the conformation of the mucus structural elements.
authors.forename: I I
authors.initials: II
authors.lastname: Degtiareva
authors.forename: N D
authors.initials: ND
authors.lastname: Opanasiuk
authors.forename: O V
authors.initials: OV
authors.lastname: Golota
authors.forename: G A
authors.initials: GA
authors.lastname: Anokhina
authors.forename: N V
authors.initials: NV
authors.lastname: Kharchenko
authors.forename: E V
authors.initials: EV
authors.lastname: Rodonezhskaia
authors.forename: O L
authors.initials: OL
authors.lastname: Palladina
authors.forename: M S
authors.initials: MS
authors.lastname: Iaremenko
authors.forename: O N
authors.initials: ON
authors.lastname: Prokopenko
authors.forename: I A
authors.initials: IA
authors.lastname: Butusova
mesh_terms: D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D004066:Digestive System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005745:Gastric Acidity Determination; D005750:Gastric Juice / Q000187:drug effects; D006801:Humans; D007421:Intestine, Small / Q000187:drug effects / Q000201:enzymology; D008297:Male; D019804:Mesalamine; D009853:Omeprazole / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D017640:Silicates / Q000494:pharmacology / Q000627:therapeutic use*; D000254:Sodium-Potassium-Exchanging ATPase / Q000187:drug effects / Q000378:metabolism
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D017640:Silicates; C016752:smecta; D019804:Mesalamine; D000254:Sodium-Potassium-Exchanging ATPase; D009853:Omeprazole